Table 137Summary evidence profile for treatments for subthreshold depressive symptoms (acceptability/tolerability data)

SSRIs versus placeboAntidepressant versus antidepressant
Leaving treatment early for any reasonRR 1.2 (0.87 to 1.65) (31.6% versus 26.3%)RR 1.02 (0.59 to 1.75) (27.8% versus 27.3%)
Quality of evidenceLowLow
Number of studies/participants (comparison)K = 2; n = 377 (paroxetine or fluoxetine)K = 1; n = 138 (sertraline versus citalopram)
Forest plot numberPharm subthreshold 02.01Pharm subthreshold 04.01
Leaving treatment early due to side effectsRR 1.55 (0.51 to 4.68) (9.1% versus 5.3%)RR 0.73 (0.31 to 1.75) (11.1% versus 15.2%)
Quality of evidenceVery lowLow
Number of studies/participants (comparison)K = 2; n = 377 (paroxetine or fluoxetine)K = 1; n = 138 (sertraline versus citalopram)
Forest plot numberPharm subthreshold 02.02Pharm subthreshold 04.04
Number reporting side effectsRR 0.76 (0.49 to 1.18) (23.6% versus 31.2%)Not reported
Quality of evidenceModerate
Number of studies/participants (comparison)K = 1; n = 215 (paroxetine)
Forest plot numberPharm subthreshold 02.03

From: 13, THE MANAGEMENT OF SUBTHRESHOLD DEPRESSIVE SYMPTOMS

Cover of Depression
Depression: The Treatment and Management of Depression in Adults (Updated Edition).
NICE Clinical Guidelines, No. 90.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2010.
Copyright © The British Psychological Society & The Royal College of Psychiatrists, 2010.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.